河北医科大学学报

• 论著 • 上一篇    下一篇

20 mg阿托伐他汀钙对无症状颈动脉不稳定斑块患者hsCRP、MMP9的影响

  

  1. 1.河北医科大学第一医院神经内科 ,河北 石家庄 050031;2.河北医科大学第一医院超声科,河北 石家庄 050031;
    3.石家庄科技职业学院制药工程系,河北 石家庄 052165
  • 出版日期:2016-07-25 发布日期:2016-08-11
  • 作者简介:解冰川(1981-),男,河北石家庄人,河北医科大学第一医院主治医师,医学学士,从事神经内科疾病诊治研究。

Impact of 20 mg atorvastatin calcium on hsCRP and MMP9 of asymptomatic carotid plaque patients

  1. 1.Department of  Neurology, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China;
    2.Department of Ultrasound, the First Hospital of Hebei Medical University, Shijiazhuang 050031, China;
    3.Department of Pharmaceutical Engineering,Shijiazhuang Vocational College of
    Science and Technology, Shijiazhuang 052165, China
  • Online:2016-07-25 Published:2016-08-11

摘要: [摘要] 目的 观察小剂量阿托伐他汀钙对无症状颈动脉不稳定斑块患者超敏 C 反应蛋白( high-sensitivityC-
reactiveprotein , hsCRP )、基质金属蛋白酶 9 ( matrixmetalloproteinase-9 , MMP-9 )的长期影响。方法 选取无症状
颈动脉不稳定斑块患者 73 例,随机分为斑块治疗组 38 例及斑块对照组 35 例,斑块治疗组给予阿司匹林肠溶片
100mg / d 、阿托伐他汀钙 20mg
/ d 口服等干预治疗;斑块对照组仅服用阿司匹林肠溶片。观察治疗前和治疗后 6 、
12 个月 hsCRP 、 MMP-9 及血脂水平的变化,并记录 2 组终点事件及不良反应情况。结果 斑块对照组 hsCRP 、
MMP-9 及低密度脂蛋白胆固醇、总胆固醇在 6 、 12 个月观察期内差异均无统计学意义( P >0.05 )。斑块治疗组 6 、
12 个月时血胆固醇、低密度脂蛋白胆固醇、 hsCRP 、 MMP-9 水平明显降低,与治疗前差异有统计学意义( P <
0.01 )。结论 小剂量阿托伐他汀钙在调脂的同时,还可通过抑制炎症介质 MMP-9 、 hsCRP 抑制炎性反应,稳定斑
块,从而预防缺血性脑血管病的发生。

关键词: 斑块, 动脉粥样硬化, 阿托伐他汀钙, C 反应蛋白质

Abstract: [
Abstract ] Objective Toobservethelong-termeffectoflowdoseatorvastatinontheserum
high-sensitivityC-reactiveprotein ( hsCRP ) and matrix metalloproteinase-9 ( MMP-9 ) among
neurologicallyasymptomaticpatients withultrasounddefinedunstablecarotidatherosclerotic
plaque.Methods Atotalof73caseswererandomlydividedintotreatmentgroup ( n =38 ) and
controlgroup ( n =35 ) .Thetreatmentgroupreceivedaspirin100mgplusatorvastatin20mgper
day , whereasthecontrolgrouponlytookaspirin100mgperday.ThelevelsofserumhsCRP
,
MMP-9 , totalcholesterol ( TC ), weremeasuredbeforeandaftertreatmentin6and12months.
Andtheendeventsandadversereactionsofthe2groupswererecorded.Results Therewasno
differenceinthelevelsofserum TC , lowdensitylipoproteincholesterol ( LDL-C ), hsCRPand
MMP-9incontrolgroup.Intreatmentgroup , thelevelsofserumTC , LDL-C , hsCRPandMMP-
9atthe6monthsand12monthsoffollow-upwerelowerthanthatbeforetreatment ( P <0.05 )  Conclusion Low-doseatorvastatinnotonlycouldregulateTC , butalsoreducethelevelsof
seruminflammatory mediators MMP-9andhsCRP , inhibitinflammatoryreactionandstable
plaque , therebypreventingtheoccurrenceofischemiccerebrovasculardisease.

Key words: plaque, atherosclerotic; atorvastatin calcium, Creactive protein